

# Gianluigi Ferretti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3483009/publications.pdf>

Version: 2024-02-01

106  
papers

2,237  
citations

185998

28  
h-index

243296

44  
g-index

106  
all docs

106  
docs citations

106  
times ranked

3204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases. <i>Breast Care</i> , 2022, 17, 330-335.	0.8	4
2	Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution. <i>Clinical Cancer Research</i> , 2021, 27, 6815-6823.	3.2	44
3	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
4	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8841.	1.8	28
5	AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8419.	1.8	14
6	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5337.	1.8	26
7	BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , 2020, 3, 546.	2.0	8
8	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e761-e770.	1.1	4
9	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. <i>Future Oncology</i> , 2020, 16, 1629-1637.	1.1	5
10	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , 2020, 9, 309.	1.8	23
11	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019, 11, 1661.	1.7	48
12	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	5.1	59
13	Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis. <i>In Vivo</i> , 2018, 32, 839-842.	0.6	2
14	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 41, 137-143.	0.9	41
15	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017, 13, 2791-2797.	1.1	23
16	Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. <i>Drug Design, Development and Therapy</i> , 2015, 9, 6177.	2.0	20
17	Bilateral spontaneous pneumothorax and massive pneumomediastinum under azopanib therapy. <i>Thoracic Cancer</i> , 2015, 6, 110-111.	0.8	2
18	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 699-706.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 1375-1388.	1.1	15
20	Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. <i>BMC Cancer</i> , 2012, 12, 482.	1.1	20
21	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. <i>Clinical Cancer Research</i> , 2011, 17, 2055-2064.	3.2	92
22	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 54.	3.5	29
23	Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2834-2835.	0.8	5
24	Improved Prognosis by Trastuzumab of Women With HER2-Positive Breast Cancer Compared With Those With HER2-Negative Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, e337-e337.	0.8	10
25	Darbepoetin Alfa and History of Thromboembolic Events. <i>Journal of Clinical Oncology</i> , 2009, 27, e211-e211.	0.8	2
26	High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. <i>Cancer Letters</i> , 2009, 282, 214-228.	3.2	24
27	Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 187-188.	1.1	0
28	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 717-725.	1.1	39
29	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , 2008, 17, 499-505.	0.9	47
30	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 197-199.	13.9	74
31	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1023-1036.	1.9	4
32	Transforming Growth Factor- $\beta$ Signaling and Regulatory T Cells. <i>Journal of Clinical Oncology</i> , 2007, 25, 4695-4696.	0.8	2
33	Re: Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1416-1416.	3.0	0
34	Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial?. <i>Journal of Clinical Oncology</i> , 2007, 25, 4320-4321.	0.8	3
35	Re: Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1344-1345.	3.0	1
36	Forkhead Box P3-Positive Regulatory T Cells As Therapeutic Target for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, e29-e29.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Zoledronic Acid and Angiogenesis. <i>Clinical Cancer Research</i> , 2007, 13, 6850-6850.	3.2	5
38	Re: Age-Related Lobular Involution and Risk of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 571-572.	3.0	3
39	Re: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1644-1644.	3.0	1
40	Old Age: Biologic Versus Chronologic. <i>Journal of Clinical Oncology</i> , 2007, 25, e8-e8.	0.8	3
41	HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 56-62.	0.9	89
42	Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin+paclitaxel in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2007, 18, 227-232.	0.7	14
43	Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. <i>Thrombosis Research</i> , 2007, 119, 525-529.	0.8	3
44	Self-monitoring versus standard monitoring of oral anticoagulation. <i>Thrombosis Research</i> , 2007, 119, 389-390.	0.8	1
45	Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. <i>Bone</i> , 2007, 41, 155-156.	1.4	5
46	Exemestane or tamoxifen?. <i>Lancet, The</i> , 2007, 369, 1599.	6.3	0
47	The protective side of progesterone. <i>Breast Cancer Research</i> , 2007, 9, 402.	2.2	1
48	Pregnancy Levels of Estrogen and Progesterone: The Double-Edged Sword. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 634.1-634.	1.1	2
49	Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients. <i>Cancer Investigation</i> , 2007, 25, 102-105.	0.6	35
50	A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. <i>Gynecologic Oncology</i> , 2007, 105, 481-492.	0.6	35
51	Progesterone, progestins, pregnancy and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 373-374.	1.1	0
52	Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 635-655.	2.2	47
53	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. <i>Supportive Cancer Therapy</i> , 2006, 3, 98-102.	0.3	15
54	Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?. <i>Chest</i> , 2006, 130, 1808-1816.	0.4	37

#	ARTICLE	IF	CITATIONS
55	Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 615-623.	1.1	20
56	Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. <i>Breast</i> , 2006, 15, 269-272.	0.9	2
57	A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. <i>Annals of Oncology</i> , 2006, 17, 630-636.	0.6	73
58	Lineage-Specific Hematopoietic Growth Factors. <i>New England Journal of Medicine</i> , 2006, 355, 526-527.	13.9	10
59	Does low-molecular-weight heparin influence cancer-related mortality?. <i>Annals of Oncology</i> , 2006, 17, 1604-1606.	0.6	7
60	Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow?. <i>Cancer Investigation</i> , 2006, 24, 466-468.	0.6	42
61	Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: What Is the Appropriate Use of Filgrastim?. <i>Journal of Clinical Oncology</i> , 2006, 24, 5618-5619.	0.8	2
62	What Is the Biological Significance of Circulating Blood Levels of Metalloproteinases?. <i>Clinical Cancer Research</i> , 2006, 12, 3550-3551.	3.2	2
63	Is There a Right-Sided Shift for Colorectal Cancer in Women Compared with Men?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1054-1054.	1.1	5
64	Trastuzumab Combined with Paclitaxel after Doxorubicin and Cyclophosphamide for Operable HER2-Positive Breast Cancer. <i>Oncologist</i> , 2006, 11, 533-533.	1.9	1
65	Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006, 24, 3048-3055.	0.8	35
66	Adjuvant Trastuzumab with Docetaxel or Vinorelbine for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2006, 11, 853-854.	1.9	8
67	Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?. <i>Annals of Oncology</i> , 2006, 17, 528-529.	0.6	2
68	Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006, 24, 5615-5616.	0.8	2
69	Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?. <i>Journal of Clinical Oncology</i> , 2006, 24, 5469-5470.	0.8	5
70	Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. <i>British Journal of Cancer</i> , 2006, 94, 1789-1796.	2.9	34
71	Liver Toxicity After Treatment With Gefitinib and Anastrozole: Drug-Drug Interactions Through Cytochrome p450?. <i>Journal of Clinical Oncology</i> , 2006, 24, e60-e61.	0.8	24
72	The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. <i>Thrombosis and Haemostasis</i> , 2006, 95, 752-754.	1.8	7

#	ARTICLE	IF	CITATIONS
73	Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?. <i>Annals of Oncology</i> , 2005, 16, 516-517.	0.6	4
74	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma. <i>Cancer</i> , 2005, 104, 1335-1342.	2.0	34
75	Lumpectomy and tamoxifen alone without additional radiotherapy for women 70½ years of age or older with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 319-319.	1.1	2
76	Low-Molecular-Weight Heparin Versus Oral Anticoagulant Therapy for the Long-Term Treatment of Symptomatic Venous Thromboembolism: Is There Any Difference in Cancer-Related Mortality?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7248-7250.	0.8	12
77	Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?. <i>Annals of Oncology</i> , 2005, 16, 1209-1210.	0.6	6
78	Can the Reliance of Hormone Receptor Assays of Surgical Specimens Be Explained by the Fluctuation of Estrogen Receptor, Progesterone Receptor, and HER-2 Protein Expression in Tumor Samples of Premenopausal Breast Cancer Patients?. <i>Journal of Clinical Oncology</i> , 2005, 23, 8918-8918.	0.8	2
79	Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005, 23, 6908-6918.	0.8	92
80	Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?. <i>Annals of Oncology</i> , 2005, 16, 1403-1404.	0.6	4
81	Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase III Study. <i>Oncology</i> , 2005, 68, 356-363.	0.9	9
82	Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients. <i>Oncology</i> , 2005, 69, 35-43.	0.9	119
83	Oxaliplatin in Colon Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1691-1692.	13.9	4
84	HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear?. <i>Journal of Clinical Oncology</i> , 2004, 22, 568-569.	0.8	5
85	Zoledronic acid-associated thrombotic thrombocytopenic purpura. <i>Annals of Oncology</i> , 2004, 15, 1847-1848.	0.6	9
86	Effect of Filgrastim on Serum Lactate Dehydrogenase and Alkaline Phosphatase Values in Early Breast Cancer Patients. <i>Cancer Investigation</i> , 2004, 22, 650-653.	0.6	5
87	New approaches to prevent intestinal toxicity of irinotecan-based regimens. <i>Cancer Treatment Reviews</i> , 2004, 30, 555-562.	3.4	90
88	Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. <i>Annals of Oncology</i> , 2004, 15, 1065-1071.	0.6	53
89	Suspected Pharmacological Interactions in a Cancer Patient During Methadone Maintenance. <i>Addictive Disorders and Their Treatment</i> , 2004, 3, 87-92.	0.5	1
90	Venous thromboembolism and cancer: new issues for an old topic. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 65-80.	2.0	38

#	ARTICLE	IF	CITATIONS
91	Subacute motor weakness and left renal mass. American Journal of Medicine, 2003, 114, 706-708.	0.6	6
92	Is there a benefit by the sequence anastrozole+formestane for postmenopausal metastatic breast cancer women?. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 107-109.	1.2	11
93	Long-Term Follow-Up in Breast Cancer Survivors: A Single Institution Survey. Journal of Women's Health, 2003, 12, 599-600.	1.5	0
94	Gastric Stump Lymphoma Five Years After Distal Gastrectomy. Leukemia and Lymphoma, 2003, 44, 365-367.	0.6	5
95	Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide. Journal of Clinical Oncology, 2003, 21, 3462-3468.	0.8	72
96	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. Acta Oncologica, 2003, 42, 693-700.	0.8	22
97	Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin. Annals of Oncology, 2003, 14, 1689-1690.	0.6	16
98	Catheter-Related Bloodstream Infections, Part II: Specific Pathogens and Prevention. Cancer Control, 2003, 10, 79-91.	0.7	3
99	Breast Cancer Metastatic to the Choroid in a Male Patient Case Report. Tumori, 2003, 89, 333-335.	0.6	4
100	Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. Drugs of Today, 2003, 39, 157.	2.4	141
101	Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients. Oncology, 2002, 63, 370-377.	0.9	7
102	Catheter-Related Bloodstream Infections, Part I: Pathogenesis, Diagnosis, and Management. Cancer Control, 2002, 9, 513-523.	0.7	7
103	Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer, 2001, 31, 267-270.	0.9	18
104	Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2. Oncology, 2001, 60, 308-312.	0.9	19
105	Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Diseases of the Colon and Rectum, 1996, 39, 1238-1244.	0.7	40
106	Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition. Frontiers in Oncology, 0, 12, .	1.3	2